Welcome!

News Feed Item

The Outlook for Pharmaceuticals in Latin America

NEW YORK, Dec. 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Outlook for Pharmaceuticals in Latin America

http://www.reportlinker.com/p0203104/The-Outlook-for-Pharmaceuticals-in-...

Strong pharmaceutical market growth opportunities and regulatory developments are making Latin America more attractive

The region needs to increase drug access, in spite of intensifying cost-containment measures. Therefore, attractive opportunities for (bio)pharmaceutical producers exist in Latin America. Brazil has the largest pharmaceutical market. Strong economic performance will fuel pharmacy sales growth in the forecast period. Mexico is the second leading market. Recent regulatory developments will create further market opportunities in the country, particularly for generic producers in both the private and public sectors. In Argentina, the pharmaceutical industry is expected to perform well in the coming years, with strong growth in production, sales, exports and employment. Pharmaceutical companies, however, are encouraged to act in smaller Latin American markets to maximise their full regional sales potential.

Generics consumption in Latin America is low, with the exception of Brazil which has a dynamic bioequivalent generic sector. In the last two years, foreign producers have penetrated what, until then, had been considered a tough sector due to local protectionism and low prices. Major developments include Pfizer's purchase of 40.0% of Teuto in November 2010, Valeant's acquisitions of two generic producers in the first half of 2010, and Sanofi's acquisition of the largest local generic company Medley in 2009. As a result, multinationals represented over 40.0% of the generic sector in 2010, compared to 12.0% in 2008. This wave of acquisitions is a blow for the government, which aims to create a leading local pharmaceutical group able to compete internationally.

In Mexico, the number of people accessing public healthcare will increase as the country is implementing universal health coverage, which means that some private pharmacy consumption will be transferred to the increasingly attractive public sector. Growth in the private pharmacy sector, therefore, is expected to be more moderate in the forecast period. Fuelled by the current economic slowdown and new regulatory measures, generics penetration in the pharmacy sector will increase and contain the private pharmacy sector by value. Strategically, Sanofi already acquired the local generic producer Kendrick in 2009, whilst Valeant acquired Tecnofarma. The amount of opportunities will be squeezed but the pharmaceutical market is large enough to be attractive in the long-term.

THESE REPORTS ANALYSE THE ISSUES

The Outlook for Pharmaceuticals in Latin America is a unique collection of management reports from Espicom Business Intelligence. Each report provides individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection, and prices include 4 completely updated reports sent quarterly, together with a comprehensive statistical appendix. There are over 60 markets covered in the worldwide series.ARGENTINAThere are over 200 pharmaceutical companies operating in the pharmacy sector, of which over half are Argentine. Local producers dominate the pharmacy sector, led by Roemmers, Bagó, Gador and Elea. Recent significant developments include the agreement to start the construction of the Polo Farmacéutico de Buenos Aires, signed by 13 local companies in October 2011; Roemmers' acquisition of 50.0% of a small local OTC company, reported in July 2011; and Roemmers' two-year agreement to distribute and sell 26 primary care products from a Swiss company, announced in January 2011. Mexico and Brazil offer more incentives for multinationals to set up their regional subsidiaries, but two foreign companies made recent strategic acquisitions in the Argentine oncology market in QIII 2011. Previously, GSK acquired Laboratorios Phoenix in June 2010.

BRAZIL

The Brazilian pharmaceutical market ranks first in the Latin American region. Pharmaceutical demand will continue to rise, fuelled by increasing disposable income, therefore the market outlook is positive for the 2011-2016 period. Generics are expected to have a pharmacy market share of 20.0% by value and 25.0% by volume in 2011. Competition among the five leading pharmacy chains is fierce, and the sector has been consolidated by a recent wave of mergers. In September 2011, Drogaria Sao Paulo, the leader in the state of Sao Paulo, and Drogarias Pacheco, the leader in Rio de Janeiro, announced a merger, creating what will be the largest pharmacy chain in Brazil, DPSP. This merger took place after the merger between Drogasil and Droga Raia, announced in August 2011, creating the second largest pharmacy chain, Raia Drogasil.

CHILEThe Chilean pharmaceutical market is expected to increase by a moderate CAGR in US dollar terms between 2011 and 2016. In July 2011, the Institute of Public Health in Chile (ISPCH – Instituto de Salud Pública de Chile) confirmed that it had sent the project to create a National Medicines Agency (ANAMED – Agencia Nacional de Medicamentos) to the Congress. The new agency is expected to update the regulation of medicines, strengthen ISPCH's regulatory functions and implement a number of measures to increase the competitiveness of the pharmaceutical industry. The creation of ANAMED is part of President Sebastián Piñera's National Policy of Medicaments that aims to ensure that medicaments sold in Chile meet efficacy, safety and equivalence standards. The industry believes that the creation of ANAMED could speed up the pharmaceutical registration process.

COLOMBIA

The pharmaceutical market in Colombia is the fourth smallest pharmaceutical market in the Latin American region. The market is set to expand at a one-digit CAGR in dollar terms between 2011 and 2016. The economic and political environment is stable, therefore the outlook is positive for pharmaceutical market growth. Colombia is looking to increase drug access for the whole population under the universal insurance programme (SGSSS), which should expand the market accordingly. Pharmaceutical imports and exports will increase. The number of pharmaceutical companies operating in the market has also risen. Gross pharmaceutical production will continue its upward trend and the industry is expected to create more employment. The leading pharmaceutical company is Tecnoquímicas, followed by Baxter, Roche, Abbott and Bayer. In February 2011, Nycomed, now acquired by Takeda, announced the acquisition of a local company.

CUBAThe economy is expected to do well in the 2011-2016 period, and the Economist Intelligence Unit (EIU) believes that mid-term economic policy is expected to be focused on making the economic system more flexible and promoting more private initiatives. The Cuban pharmaceutical market is the smallest in the Latin American region but, based on current research, production and trade trends, Espicom projects a moderate CAGR in dollar terms between 2011 and 2016. The Cuban pharmaceutical market increased in value by five times in the 2075-2010 period. Cuba has developed a well-established pharmaceutical industry based on the formulation or manufacturing of generic medicines. An important Cuban biotechnology industry has also been developed. The government is responsible for domestic production, which represents between 80% and 90% of the market.

MEXICO

Generic sales in Mexico are still negligible in the private pharmacy sector. However, the National Association of Interchangeable Generic Medicines (AMEGI) believes that consumption of generic medicines in the private pharmacy sector will increase considerably in the forecast period. A number of patents for bestselling drugs will expire in the coming years, and this will accelerate generic market growth. Generic sales are high, when considering sales in the public sector. The public sector is accountable for about 80.0% of generic sales by value, whilst the private pharmacy sector represents the remaining 20.0%; generic sales represented 3.5% of pharmacy sales. In terms of competition, a number of foreign producers, i.e. Sanofi and Valeant, have acquired a couple of local producers, whilst others have formed partnerships with local producers.

PERUThe Peruvian pharmaceutical market is the second smallest in the region. The market is expected to increase by a moderate CAGR in dollar terms between 2011 and 2016. Pharmaceutical expenditure per capita is the lowest in the region. This means that there are growth opportunities, as the economy is expected to perform well in the forecast period. The market increased five times between 2075 and 2010. In January 2011, the Israeli company Teva Pharmaceutical Industries announced that it was acquiring Infarmasa from The Rohatyn Group (TRG) and Altra Investments. Teva commented that the combination of Medco, which is Teva's existing operation in Peru, and Infarmasa would create one of the top two pharmaceutical companies in the country.

VENEZUELA

Inflation rates are expected to remain extremely high in the forecast period, over-inflating the Venezuelan pharmaceutical market in local terms. GDP growth, particularly from 2012 onwards, and population growth are expected to encourage pharmaceutical sales, in spite of drug price controls and currency exchange controls. MPPS will continue to implement Barrio Adentro, but threats in the public sector include government drug imports from countries that co-operate with Venezuela and government pharmaceutical production. Espicom projects the Venezuelan market to rank as the fourth largest in the Latin American region in 2016. OTC and generic sales are expected to increase in the forecast period. There are about 33 pharmaceutical producers, most of which are local. Foreign producers have consolidated their regional operations in other countries in the last ten years, but Bayer, Daiichi Sankyo, Pfizer, Sanofi, La Sante and Teva remain.

To order this report:Pharmacies_and_Drug_Stores Industry: The Outlook for Pharmaceuticals in Latin America

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
The essence of cloud computing is that all consumable IT resources are delivered as services. In his session at 15th Cloud Expo, Yung Chou, Technology Evangelist at Microsoft, demonstrated the concepts and implementations of two important cloud computing deliveries: Infrastructure as a Service (IaaS) and Platform as a Service (PaaS). He discussed from business and technical viewpoints what exactly they are, why we care, how they are different and in what ways, and the strategies for IT to transi...
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists l...
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership abi...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., will discuss how these tools can be leveraged to develop a lasting competitive advanta...
TechTarget storage websites are the best online information resource for news, tips and expert advice for the storage, backup and disaster recovery markets. By creating abundant, high-quality editorial content across more than 140 highly targeted technology-specific websites, TechTarget attracts and nurtures communities of technology buyers researching their companies' information technology needs. By understanding these buyers' content consumption behaviors, TechTarget creates the purchase inte...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, will discuss some of the security challenges of the IoT infrastructure and relate how these aspects impact Smart Living. The material will be delivered i...
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), will provide an overview of various initiatives to certifiy the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldw...
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...